Shanghai Genomics forms collaboration with Centocor

The collaboration, which will involve biological research aimed at understanding inflammatory signaling pathways, will initially last for a period of one and a half years.

Shanghai Genomics, an affiliate of Tokyo headquartered biopharmaceutical company GNI, will use its expertise in protein purification and cell-based interaction assays to explore receptor protein interactions and intracellular signaling cascades with Centocor. In particular, the research will focus upon the areas of inflammation and oncology.

“Shanghai Genomics is delighted to be collaborating with Centocor on this exciting project,” said Ying Luo, president and CEO Shanghai Genomics. “This is yet another validation of the model we have refined with GNI, where we are the first company to combine innovative Western science with cost-efficient research capabilities in China, and access to the Chinese and Japanese pharmaceutical markets.”